Working... Menu

Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03059030
Recruitment Status : Recruiting
First Posted : February 23, 2017
Last Update Posted : March 7, 2019
BTG International Inc.
Information provided by (Responsible Party):
Riad Salem, Northwestern University

Brief Summary:
Evaluate the safety and efficacy of Yttrium-90 (90Y) radioembolization for the management of thrombocytopenia.

Condition or disease Intervention/treatment Phase
Thrombocytopenia Cirrhosis Device: TheraSphere® Yttrium-90 Glass Microspheres, BTG International Inc. Not Applicable

Detailed Description:
This protocol will provide access to TheraSphere® treatment for patients who have refractory thrombocytopenia secondary to cirrhosis. This protocol will utilize splenic artery-directed TheraSphere® treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia
Actual Study Start Date : March 16, 2017
Estimated Primary Completion Date : April 1, 2019
Estimated Study Completion Date : April 1, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cirrhosis
Drug Information available for: Yttrium

Arm Intervention/treatment
Experimental: Subjects with thrombocytopenia secondary to cirrhosis
Evaluate the safety and efficacy of 90Y radioembolization for the management of thrombocytopenia.
Device: TheraSphere® Yttrium-90 Glass Microspheres, BTG International Inc.
The Interventional Radiologists will inject a dose of Yttrium 90 into your spleen through a small catheter placed in your femoral artery.The entire treatment visit is an outpatient procedure. You will only be admitted to the hospital if the physician deems it necessary due to any symptoms you may experience after the treatment is given. This visit may take 6 to 8 hours.

Primary Outcome Measures :
  1. Safety of 90Y Radioembolization (RE) for the treatment of thrombocytopenia in the setting of cirrhosis, evaluated by the number of participants with treatment-related adverse events as assessed by CTCAE v4.0. [ Time Frame: 6 months ]
    Assess for infection after Y90 treatment to the spleen by physical exam noted by a change in vital signs and lab values such as white blood count at each follow up visit.

  2. Safety of 90Y RE for the treatment of thrombocytopenia in the setting of cirrhosis. [ Time Frame: 6 months ]
    Assess for splenic abscess after Y90 to the spleen as seen on follow up CT imaging at 1, 3, and 6 months post treatment. This will also be evaluated at all visits by physical exam, fever, pain, and lab work. Visits occur at 2, 4, 6, 8 weeks, 3, 4, 5, 6 months.

  3. Safety of 90Y RE for the treatment of thrombocytopenia in the setting of cirrhosis. [ Time Frame: 6 months ]
    Assess for any adverse events after Y90 administration at follow visits or outside visits if they occur by physical exam and lab values at baseline, 2, 4, 6, 8 weeks, 3, 4, 5, 6 months post treatment. Lab value changes, ascites, fatigue, fever, nausea, dyspepsia, abdominal pain, pleural effusion, GI ulcer, pneumonitis, and thromboembolic events will be followed closely.

  4. Asses the need for Technetium albumin aggregated (TC-MAA 99m) injection to determine shunting prior to Y90 administration [ Time Frame: 6 months ]
    MAA injection will be done and nuclear medicine PET scan to evaluate shunting and evaluated for the first 5 patients. If shunt is <5% subsequently enrolled patients will not undergo MAA, if shunt is >5% all subsequent patients will undergo MAA. This will be evaluated post MAA injection before Y90 treatment.

Secondary Outcome Measures :
  1. Evaluate platelet count 6 months after treatment [ Time Frame: 6 months ]
    Complete Blood Count with platelets will be drawn at baseline, treatment, 2, 4, 6, 8 weeks and 3, 4, 5, 6 months post treatment

  2. Evaluate splenic volume post procedure [ Time Frame: 6 months ]
    CT or MR of the abdomen will be done at screening, 4 weeks, 3 months, and 6 months after Y90 administration

  3. Evaluate length of hospital stay after procedure [ Time Frame: 6 months ]
    Length of stay in days will be recorded post procedure

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female, 18 years of age or older, of any ethnic or racial group.
  • Diagnosis of cirrhosis or portal hypertension with a serum platelet count less than or equal to 80 × 109/L. [Rationale: platelet count <100 × 109/L triples the rate of liver-related adverse events (3) and worsens postoperative survival in the setting of hepatocellular carcinoma (HCC) (4). Initial platelet count of 80 × 109/L can allow the majority of patients who successfully respond to 90Y-RE (clinical endpoint of 50% platelet count increase) to exceed the 100 × 109/L threshold.]

Cirrhosis is defined by one of three criteria:

  • Liver Biopsy/histology consistent with cirrhotic architectural liver changes
  • Portal hypertension (Hepatic venous pressure gradient ≥10 mm Hg)
  • Evidence of esophageal and/or gastric varices
  • Patients must have evidence of splenomegaly as determined by screening cross-sectional imaging.
  • No evidence of myelosuppression (e.g. lymphopenia) as evidenced by normal hematology values at Screening
  • Adequate baseline organ function(with the exception of cirrhosis) as evidenced by normal BUN/Cr and electrolytes on screening chemistry.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-2
  • Patient has a life expectancy of greater than 6 months without intervention.
  • Patient is willing to participate in the study and has signed the study informed consent.
  • Women of childbearing potential must have a negative serum pregnancy test within 28 days prior to screening and must not be breastfeeding.

Exclusion Criteria:

  • Patients with serum platelet count less than 10 × 109/L.
  • History of bleeding disorder attributed to another cause other than cirrhosis (e.g. Von Willebrand disease)
  • Declines or unable to provide informed consent
  • History of prior partial splenic embolization (PSE) or splenectomy
  • Use of any medication known to increase platelet count 1 month prior to Baseline.
  • History of allergy or sensitivity to TheraSphere® or its components.
  • History of severe peripheral allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically
  • Contraindications to angiography and selective visceral catheterization such as bleeding, diathesis or coagulopathy that is not correctable by usual therapy or hemostatic agents (e.g. closure device)
  • Previous randomization in a trial using 90Y RE
  • Patient must not have participated or enrolled in a clinical trial with an investigational device / therapy within 30 days prior to randomization
  • Any serious medical condition likely to impede successful completion of the study, such as certain mental disorders, cardiac arrhythmias, and uncontrolled congestive heart failure or respiratory disease.
  • Patients actively on chemotherapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03059030

Layout table for location contacts
Contact: Carlene del Castillo, RN 312-695-1518
Contact: Riad Salem, MD MBA 312-695-6371

Layout table for location information
United States, Illinois
Northwestern University/Northwestern Memorial Hospital Recruiting
Chicago, Illinois, United States, 60611
Contact: Riad Salem, MD MBA    312-695-6371   
Contact: Carlene del Castillo, RN    312-695-1518   
Principal Investigator: Riad Salem, MD MBA         
Sub-Investigator: Robert Lewandowski, MD         
Sub-Investigator: Daniel Ganger, MD         
Sub-Investigator: Laura Kulik, MD         
Sub-Investigator: Young K Chae, MD         
Sub-Investigator: John Hayes, MD         
Sponsors and Collaborators
Northwestern University
BTG International Inc.
Layout table for investigator information
Principal Investigator: Riad Salme, MD Northwestern University

Layout table for additonal information
Responsible Party: Riad Salem, Chief, Vascular and Interventional Radiology, Northwestern University Identifier: NCT03059030     History of Changes
Other Study ID Numbers: STU 00203772
First Posted: February 23, 2017    Key Record Dates
Last Update Posted: March 7, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No

Keywords provided by Riad Salem, Northwestern University:

Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Cirrhosis
Pathologic Processes
Liver Diseases
Digestive System Diseases
Blood Platelet Disorders
Hematologic Diseases